Global Information
회사소개 | 문의 | 비교리스트

세계의 재조합 DNA(rDNA) 기술 시장 : 성장, 동향, 예측(2019-2024년)

Recombinant DNA (rDNA) Technology Market - Growth, Trends, and Forecast (2019 - 2024)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2019년 05월 상품 코드 707232
페이지 정보 영문
가격
US $ 4,250 ₩ 5,129,000 PDF (Single User License)
US $ 4,750 ₩ 5,733,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,242,000 PDF (Site License)
US $ 7,500 ₩ 9,052,000 PDF (Corporate License)


세계의 재조합 DNA(rDNA) 기술 시장 : 성장, 동향, 예측(2019-2024년) Recombinant DNA (rDNA) Technology Market - Growth, Trends, and Forecast (2019 - 2024)
발행일 : 2019년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 재조합 DNA(rDNA, Recombinant DNA) 기술 시장에 대해 조사 분석했으며, 시장 개요, 부문 및 지역별 시장 규모 추이와 예측, 시장 동향, 시장 성장 촉진요인 및 저해요인 분석, 시장 기회, 경쟁 구도, 주요 기업 개요 등의 정보를 제공합니다.

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 제품별
    • 의약품
    • 의약품 이외
  • 구성요소별
    • 발현 시스템
    • 클로닝 벡터
  • 용도별
    • 식품 및 농업
    • 건강 및 질환
    • 환경
    • 기타
  • 최종사용자별
    • 바이오테크놀러지 기업 및 제약 기업
    • 학술기관 및 정부 연구기관
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Amgen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd(Genentech Inc.)
    • GenScript
    • Merck KGaA
    • New England Biolabs
    • Novartis AG
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Sanofi

제7장 시장 기회 및 향후 동향

LSH 19.07.01

Market Overview

Recombinant DNA technology (RDT) is performing a vital role in improving health conditions by developing new vaccines and pharmaceuticals. The treatment strategies are also improved by developing diagnostics kits, monitoring devices, and new therapeutic approaches. Additionally, many other industries are getting benefit from the Genetically Modified Organism (GMO) research such as microorganisms are being considered as future clean fuel producers and bio degrader. Genetically modified vaccines are developed for curing various diseases in human and plants. The recombinant DNA technology has created several potential innovation opportunities for developing a wide range of therapeutic products, with immediate effect in the medical genetics and biomedicine by modifying microorganisms, animals, and plants to yield medically useful substances. So, increasing demand, as well as the application of RDT in various sectors are acting as a major driver for the growth of the market.

Scope of the Report

Recombinant DNA technology is a process in which creation and manipulation of the DNA sequences are in a specific order that is resulting in the production of genetically modified organism and product. The potential usage of recombinant DNA in conventional and non- conventional application, such as medicinal, agricultural, and industrial. In medicine, Recombinant DNA has been used to mass production of insulin, follistim, human growth hormones, monoclonal antibodies, human albumin, vaccines, and other drugs.

Key Market Trends

Food and Agriculture is Expected to Grow with High CAGR in the Forecasted Period

In agriculture development of genetically modified crops, with a purpose to improve both yield and resistance to plant pests, or herbicides seems to have gained a degree of public acceptance and is already practiced in a commercial context in several countries. The genetically modified tomato CGN-89564-2 was the first commercially grown, genetically engineered crop product to be granted a license for human consumption. Additionally, DNA molecular marker technology is important for preservation, identification, evaluation, mining, and innovation of plant germplasm resources. The introduction of a genetically modified fruit paved the way for use of GMOs in food, and today genetic modification is widespread. According to Journal of Applied Biotechnology and Bioengineering in 2016, in the United States, 88% of corn and 93% of soybeans are genetically altered and much of this finds it's way unlabeled into processed foods. Thus, increased application of RDT in agriculture and food is augmenting the growth of the market.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. In the North America region, the United States holds the largest market share and this is due to the presence of number of biopharmaceutical manufacturing companies and presence of effective regulatory bodies to monitor the various ethical and scientific concerns, pertaining to the use of technology which has helped the growth of the Recombinant DNA (rDNA) Technology market in the country.

Competitive Landscape

The Recombinant DNA (rDNA) Technology market is competitive and consists of a major players and small players. In terms of market share, these major players currently dominate the market. Some of the major players of the market are GenScript, New England Biolabs, GlaxoSmithKline plc, Pfizer , Sanofi are among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements in Genomics
    • 4.2.2 Expansion of Biopharmaceutical Industry
    • 4.2.3 Increasing Demand as well as Application of Recombinant/ Genetically Modified Products
  • 4.3 Market Restraints
    • 4.3.1 Regulatory, Scientific, and Ethical Challenges Associated with Gene Therapy
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Medical
      • 5.1.1.1 Therapeutic Agent
      • 5.1.1.2 Human Protein
      • 5.1.1.3 Vaccine
    • 5.1.2 Non-medical
      • 5.1.2.1 Biotech Crops
      • 5.1.2.2 Specialty Chemicals
      • 5.1.2.3 Others
  • 5.2 By Component
    • 5.2.1 Expression System
    • 5.2.2 Cloning Vector
  • 5.3 By Application
    • 5.3.1 Food and Agriculture
    • 5.3.2 Health and Disease
    • 5.3.3 Environment
    • 5.3.4 Others
  • 5.4 By End User
    • 5.4.1 Biotechnology and Pharmaceutical Companies
    • 5.4.2 Academic and Government Research Institutes
    • 5.4.3 Others
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 US
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 UK
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 Eli Lilly and Company
    • 6.1.3 F. Hoffmann-La Roche Ltd (Genentech Inc.)
    • 6.1.4 GenScript
    • 6.1.5 Merck KGaA
    • 6.1.6 New England Biolabs
    • 6.1.7 Novartis AG
    • 6.1.8 Novo Nordisk A/S
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Sanofi

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q